
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1169708/publications.pdf Version: 2024-02-01



ΙΙΔΝΙ-ΟΛΟ ΕΔΝΙ

#	Article	IF	CITATIONS
1	A Global Survey of Physicians Knowledge About Nonalcoholic Fatty Liver Disease. Clinical Gastroenterology and Hepatology, 2022, 20, e1456-e1468.	4.4	49
2	Histone deacetylase inhibitor givinostat attenuates nonalcoholic steatohepatitis and liver fibrosis. Acta Pharmacologica Sinica, 2022, 43, 941-953.	6.1	9
3	Clinical and Patient-Reported Outcomes From Patients With Nonalcoholic Fatty Liver Disease Across the World: Data From the Global Non-Alcoholic Steatohepatitis (NASH)/ Non-Alcoholic Fatty Liver Disease (NAFLD) Registry. Clinical Gastroenterology and Hepatology, 2022, 20, 2296-2306.e6.	4.4	35
4	Prevalence and characteristics of MAFLD in Chinese adults aged 40 years or older: A community-based study. Hepatobiliary and Pancreatic Diseases International, 2022, 21, 154-161.	1.3	24
5	Editorial: opposite effects of genetic polymorphisms known to induce <scp>NAFLD</scp> on hepatic and cardiovascular outcomes in Chinese population. Alimentary Pharmacology and Therapeutics, 2022, 55, 876-877.	3.7	1
6	Global multi-stakeholder endorsement of the MAFLD definition. The Lancet Gastroenterology and Hepatology, 2022, 7, 388-390.	8.1	135
7	Association of maternal obesity and gestational diabetes mellitus with overweight/obesity and fatty liver risk in offspring. World Journal of Gastroenterology, 2022, 28, 1681-1691.	3.3	5
8	Acute Hepatitis of Unknown Origin in Children: Early Observations from the 2022 Outbreak. Journal of Clinical and Translational Hepatology, 2022, 10, 522-530.	1.4	19
9	Does nonalcoholic fatty liver disease predispose patients to carotid arteriosclerosis and ischemic stroke?. Clinical and Molecular Hepatology, 2022, 28, 473-477.	8.9	2
10	The gut mycobiome: a novel player in chronic liver diseases. Journal of Gastroenterology, 2021, 56, 1-11.	5.1	22
11	What are the clinical settings and outcomes of lean NAFLD?. Nature Reviews Gastroenterology and Hepatology, 2021, 18, 289-290.	17.8	24
12	Efficacy of Intragastric Balloons in the Markers of Metabolic Dysfunction-associated Fatty Liver Disease: Results from Meta-analyses. Journal of Clinical and Translational Hepatology, 2021, 000, 000-000.	1.4	2
13	Simple nonâ€invasive scoring systems and histological scores in predicting mortality in patients with nonâ€alcoholic fatty liver disease: A systematic review and metaâ€analysis. Journal of Gastroenterology and Hepatology (Australia), 2021, 36, 1754-1768.	2.8	5
14	Diagnostic Performance of FibroTouch Ultrasound Attenuation Parameter and Liver Stiffness Measurement in Assessing Hepatic Steatosis and Fibrosis in Patients With Nonalcoholic Fatty Liver Disease. Clinical and Translational Gastroenterology, 2021, 12, e00323.	2.5	22
15	Multidisciplinary participation: the key to cure for nonâ€alcoholic fatty liver disease. Journal of Digestive Diseases, 2021, , .	1.5	1
16	Fibroblast Growth Factor 19 in Gestational Diabetes Mellitus and Fetal Growth. Frontiers in Endocrinology, 2021, 12, 805722.	3.5	4
17	Lipotoxic Hepatocyteâ€Derived Exosomal MicroRNA 192â€5p Activates Macrophages Through Rictor/Akt/Forkhead Box Transcription Factor O1 Signaling in Nonalcoholic Fatty Liver Disease. Hepatology, 2020, 72, 454-469.	7.3	170
18	Nonâ€alcoholic fatty liver disease to metabolic dysfunctionâ€associated fatty liver disease : Conceptual changes for clinicians, researchers and patients. Journal of Digestive Diseases, 2020, 21, 604-609.	1.5	5

#	Article	IF	CITATIONS
19	The Asian Pacific Association for the Study of the Liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease. Hepatology International, 2020, 14, 889-919.	4.2	422
20	APOC3 rs2070667 Associates with Serum Triglyceride Profile and Hepatic Inflammation in Nonalcoholic Fatty Liver Disease. BioMed Research International, 2020, 2020, 1-9.	1.9	6
21	Unhealthy lifestyle habits and physical inactivity among Asian patients with nonâ€alcoholic fatty liver disease. Liver International, 2020, 40, 2719-2731.	3.9	32
22	Effects and therapeutic mechanism of Yinzhihuang on steatohepatitis in rats induced by a highâ€fat, highâ€cholesterol diet. Journal of Digestive Diseases, 2020, 21, 179-188.	1.5	7
23	A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement. Journal of Hepatology, 2020, 73, 202-209.	3.7	2,171
24	Prevalence, clinical characteristics, risk factors, and indicators for lean Chinese adults with nonalcoholic fatty liver disease. World Journal of Gastroenterology, 2020, 26, 1792-1804.	3.3	34
25	Gamma-glutamyl transferase and cardiovascular risk in nonalcoholic fatty liver disease: The Gut and Obesity Asia initiative. World Journal of Gastroenterology, 2020, 26, 2416-2426.	3.3	9
26	Letter: moderateâ€ŧoâ€severe hepatic steatosis leads to overestimation of liver stiffness measurement in chronic hepatitis B patients without significant fibrosis. Authors' reply. Alimentary Pharmacology and Therapeutics, 2019, 50, 617-618.	3.7	0
27	Editorial: effect of hepatic steatosis on liver stiffness in patients with chronic hepatitis B—authors' reply. Alimentary Pharmacology and Therapeutics, 2019, 50, 334-335.	3.7	1
28	Moderate to severe hepatic steatosis leads to overestimation of liver stiffness measurement in chronic hepatitis B patients without significant fibrosis. Alimentary Pharmacology and Therapeutics, 2019, 50, 93-102.	3.7	35
29	Post-translational regulation of lipogenesis via AMPK-dependent phosphorylation of insulin-induced gene. Nature Communications, 2019, 10, 623.	12.8	95
30	Obesity and nonalcoholic fatty liver disease associated with adenocarcinoma in patients with lung cancer. Medicine (United States), 2019, 98, e17098.	1.0	10
31	Guidelines of prevention and treatment of nonalcoholic fatty liver disease (2018, China). Journal of Digestive Diseases, 2019, 20, 163-173.	1.5	111
32	Guidelines of prevention and treatment for alcoholic liver disease (2018, China). Journal of Digestive Diseases, 2019, 20, 174-180.	1.5	16
33	Noninvasive diagnosis of nonalcoholic steatohepatitis: Emerging approaches. Hepatobiliary and Pancreatic Diseases International, 2019, 18, 1-3.	1.3	2
34	Genome-wide analysis of DNA methylation in human peripheral leukocytes identifies potential biomarkers of nonalcoholic fatty liver disease. International Journal of Molecular Medicine, 2018, 42, 443-452.	4.0	12
35	circRNA_0046366 inhibits hepatocellular steatosis by normalization of PPAR signaling. World Journal of Gastroenterology, 2018, 24, 323-337.	3.3	72
36	New trends on obesity and NAFLD in Asia. Journal of Hepatology, 2017, 67, 862-873.	3.7	759

#	Article	IF	CITATIONS
37	Prolyl oligopeptidase attenuates hepatic stellate cell activation through induction of Smad7 and PPAR-Î3. Experimental and Therapeutic Medicine, 2017, 13, 780-786.	1.8	11
38	Individual patient data meta-analysis of controlled attenuation parameter (CAP) technology for assessing steatosis. Journal of Hepatology, 2017, 66, 1022-1030.	3.7	734
39	Serum Monounsaturated Triacylglycerol Predicts Steatohepatitis in Patients with Non-alcoholic Fatty Liver Disease and Chronic Hepatitis B. Scientific Reports, 2017, 7, 10517.	3.3	18
40	Steatosis induced CCL5 contributes to early-stage liver fibrosis in nonalcoholic fatty liver disease progress. Translational Research, 2017, 180, 103-117.e4.	5.0	46
41	PNPLA3rs1010023 Predisposes Chronic Hepatitis B to Hepatic Steatosis but Improves Insulin Resistance and Glucose Metabolism. Journal of Diabetes Research, 2017, 2017, 1-12.	2.3	4
42	Circular RNA Profiling and Bioinformatic Modeling Identify Its Regulatory Role in Hepatic Steatosis. BioMed Research International, 2017, 2017, 1-13.	1.9	50
43	circRNA_0046367 Prevents Hepatoxicity of Lipid Peroxidation: An Inhibitory Role against Hepatic Steatosis. Oxidative Medicine and Cellular Longevity, 2017, 2017, 1-16.	4.0	77
44	Hepatitis B Virus (HBV) Infection and Hepatocellular Carcinoma- New Insights for an Old Topic. Current Cancer Drug Targets, 2017, 17, 505-511.	1.6	17
45	Will Sofosbuvir/Ledipasvir (Harvoni) Be Cost-Effective and Affordable for Chinese Patients Infected with Hepatitis C Virus? An Economic Analysis Using Real-World Data. PLoS ONE, 2016, 11, e0155934.	2.5	34
46	APOC3 rs2070666 Is Associated with the Hepatic Steatosis Independently of PNPLA3 rs738409 in Chinese Han Patients with Nonalcoholic Fatty Liver Diseases. Digestive Diseases and Sciences, 2016, 61, 2284-2293.	2.3	22
47	Comparison of real-time contrast-enhanced ultrasonography and standard ultrasonography in liver cancer microwave ablation. Experimental and Therapeutic Medicine, 2016, 12, 1345-1348.	1.8	12
48	The clinical effect and relevant mechanism of combined sorafenib and radiofrequency ablation in the treatment of early small hepatocellular carcinoma. Oncology Letters, 2016, 12, 951-955.	1.8	8
49	Modulation of Gut Microbiota by Berberine Improves Steatohepatitis in High-Fat Diet-Fed BALB/C Mice. Archives of Iranian Medicine, 2016, 19, 197-203.	0.6	45
50	Impact of skin capsular distance on the performance of controlled attenuation parameter in patients with chronic liver disease. Liver International, 2015, 35, 2392-2400.	3.9	71
51	Hyperinsulinemia shifted energy supply from glucose to ketone bodies in early nonalcoholic steatohepatitis from high-fat high-sucrose diet induced Bama minipigs. Scientific Reports, 2015, 5, 13980.	3.3	29
52	Thyroid function is associated with nonâ€alcoholic fatty liver disease in chronic hepatitis <scp>B</scp> â€infected subjects. Journal of Gastroenterology and Hepatology (Australia), 2015, 30, 1753-1758.	2.8	20
53	Fuzheng Huayu Recipe Ameliorates Liver Fibrosis by Restoring Balance between Epithelial-to-Mesenchymal Transition and Mesenchymal-to-Epithelial Transition in Hepatic Stellate Cells. BioMed Research International, 2015, 2015, 1-11.	1.9	16
54	Potential Epigenetic Mechanism in Non-Alcoholic Fatty Liver Disease. International Journal of Molecular Sciences, 2015, 16, 5161-5179.	4.1	81

#	Article	IF	CITATIONS
55	Prevalence of and Risk Factors for Type 2 Diabetes Mellitus in Hyperlipidemia in China. Medical Science Monitor, 2015, 21, 2476-2484.	1.1	40
56	Potential Applications of Induced Pluripotent Stem Cells (iPSCs) in Hepatology Research. Current Stem Cell Research and Therapy, 2015, 10, 208-215.	1.3	7
57	Linked <i>PNPLA3</i> polymorphisms confer susceptibility to nonalcoholic steatohepatitis and decreased viral load in chronic hepatitis B. World Journal of Gastroenterology, 2015, 21, 8605.	3.3	21
58	Saturated Fatty Acid Inhibits Viral Replication in Chronic Hepatitis B Virus Infection With Nonalcoholic Fatty Liver Disease by Toll-Like Receptor 4-Mediated Innate Immune Response. Hepatitis Monthly, 2015, 15, e27909.	0.2	30
59	β-catenin is overexpressed in hepatic fibrosis and blockage of Wnt/β-catenin signaling inhibits hepatic stellate cell activation. Molecular Medicine Reports, 2014, 9, 2145-2151.	2.4	86
60	Controlled attenuation parameter for non-invasive assessment of hepatic steatosis in Chinese patients. World Journal of Gastroenterology, 2014, 20, 4702.	3.3	92
61	High-saturate-fat diet delays initiation of diethylnitrosamine-induced hepatocellular carcinoma. BMC Gastroenterology, 2014, 14, 195.	2.0	25
62	Hepatic Steatosis Is Highly Prevalent in Hepatitis B Patients and Negatively Associated with Virological Factors. Digestive Diseases and Sciences, 2014, 59, 2571-2579.	2.3	74
63	NAFLD leads to liver cancer: Do we have sufficient evidence?. Cancer Letters, 2014, 345, 230-234.	7.2	54
64	RNAi screening with shRNAs against histone methylation-related genes reveals determinants of sorafenib sensitivity in hepatocellular carcinoma cells. International Journal of Clinical and Experimental Pathology, 2014, 7, 1085-92.	0.5	14
65	Regulation of adipokines by polyunsaturated fatty acids in a rat model of non-alcoholic steatohepatitis. Archives of Iranian Medicine, 2014, 17, 563-8.	0.6	10
66	Role of diet and nutritional management in nonâ€alcoholic fatty liver disease. Journal of Gastroenterology and Hepatology (Australia), 2013, 28, 81-87.	2.8	127
67	Guidelines for the diagnosis and management of nonalcoholic fatty liver disease: Update 2010. Journal of Digestive Diseases, 2011, 12, 38-44.	1.5	227
68	A tribute to Dr Guang-bi Yao (1931-2010). Journal of Gastroenterology and Hepatology (Australia), 2010, 25, 1027-1028.	2.8	0
69	Prevention of hepatocellular carcinoma in nonviralâ€related liver diseases. Journal of Gastroenterology and Hepatology (Australia), 2009, 24, 712-719.	2.8	35
70	Epidemiology of non-alcoholic fatty liver disease in China. Journal of Hepatology, 2009, 50, 204-210.	3.7	444
71	Commonly used animal models of non-alcoholic steatohepatitis. Hepatobiliary and Pancreatic Diseases International, 2009, 8, 233-40.	1.3	47